InterMune to Conduct Conference Call and Webcast to Discuss Results of Triple Combination Study of ITMN-191
Posted on: Friday, 9 January 2009, 15:01 CST
To access the live teleconference, dial 888-799-0528 (U.S.) or 973-200-3372 (international), conference ID# 80676348. To access the live audio webcast of the conference call, please log on to the investor relations page of the company's website at http://www.intermune.com. The company recommends logging on to the site 15 minutes prior to the start of the presentation in order to register or download any necessary software.
A replay of the webcast and teleconference will be available approximately three hours after the call. The teleconference replay will be available for 10 business days following the call and can be accessed by dialing 800-642-1687 (U.S.) or 706-645-9291 (international), and entering the conference ID# 80676348.
About InterMune
InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and hepatology. InterMune has a research and development portfolio addressing idiopathic pulmonary fibrosis (IPF) and hepatitis C virus (HCV) infections. The pulmonology portfolio includes the Phase 3 program, CAPACITY, which is evaluating pirfenidone for the treatment of patients with IPF and a research program focused on small molecules for pulmonary disease. The hepatology portfolio includes the HCV protease inhibitor compound ITMN-191 (referred to as R7227 at Roche) in Phase 1b, a second-generation HCV protease inhibitor research program, and a research program evaluating a new target in hepatology. For additional information about InterMune and its R&D pipeline, please visit htpp://www.intermune.com.
SOURCE InterMune, Inc.
Source: PR Newswire
Related Articles
- JetBlue to Webcast Presentation at the Next Generation Equity Research Airline Conference
- Delta to Present at Next Generation Equity Research Airline Conference
- BMP Sunstone to be Featured on SIG's 'China Healthcare On Call' Conference Call Series
- Spartan Motors to Attend the Barrington Research Industrial Conference on May 21; Showcasing FRAC Emergency-Rescue Vehicle at Event
- Harbin Electric to Present at Oppenheimer 3rd Annual China Dragon Call Conference on May 19, 2009
- Acorn to Present at CCG China Rising Investment Conference and Oppenheimer 3rd Annual China Dragon Call Conference
- BNY ConvergEx Group's BNY Jaywalk Announces Independent Research Provider Performance Award Program
- Google to Present at the Citi Investment Research Technology Conference
- Tumor Targeting Docetaxel Abstract Selected for Presentation at the 11th Liposome Research Days Conference
- NexGenix Pharmaceuticals Presents Data on a Novel Small Molecule Inhibitor of Heat Shock Protein 90 (Hsp90) at the GTCbio Cancer Drugs Research & Development Conference
 |
 |
User Comments (0)
RSS Feeds